


S/N Unknown

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	JUNIEN et al.	Examiner:	Unknown
Serial No.:	Unknown	Group Art Unit:	Unknown
Filed:	February 15, 2006	Docket No.:	11123.0104USWO
Title:	PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF METFORMIN AND A STATIN		

<p>CERTIFICATE UNDER 37 CFR 1.10: "Express Mail" mailing label number: EV 495845037 US Date of Deposit: February 15, 2006</p> <p>I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.</p> <p style="text-align: right;">By:  Name: John Junka</p>	
--	--

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Mail Stop PCT
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, Virginia 22313-1450

Dear Commissioner:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. At least some of the references were cited in an International Search Report mailed February 12, 2004.

This statement should be considered because it is submitted within three months of the filing date of the above-identified application, which is not an application under 37 C.F.R. § 1.53(d). Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. § 1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided. Enclosed for the Examiner's information is a copy of the International Search Report.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a

reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.


Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.



Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, MN 55402-0903
(612)332.5300

Dated: 2/15/06

By: 
Gregory A. Sebald
Reg. No.: 33,280

GAS/ncb

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11123.0104USWO	Application Number: Unknown
	Applicant: JUNIEN et al.	
	Filing Date: February 15, 2006	Group Art Unit: Unknown

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Zunzunegui-Pastor et al. "Effects of Candesartan, Metaformin and Pravastatin Combination on Cardiovascular Risk Factors in a Poor Controlled Hypertensive Population with Chronic Metabolic Syndrome" American Journal of Hypertension Vol 14, No. 4. Part 2.
		Carlsen et al. "Evidence of dissociation of insulin- and weight-reducing effects of metformin in non-diabetic male patients with coronary heart disease" Diabetes Research and Clinical Practice 39 (1998) p. 47-54.
		Carlsen et al. "Metformin increases circulating tumour necrosis factor- α levels in non-obese non-diabetic patients with coronary heart disease" Cytokine, Vol. 10 No. 1 (January), 1998 P. 66-69
		Alsheikh-Ali et al. "Risk of Adverse Events With Concomitant Use of Atorvastatin or Simvastatin and Glucose-Lowering Drugs (Thiazolidinediones, Metformin, Sulfonylurea, Insulin and Acarbose) " The American Journal of Cardiology, Vol 89 June 1, 2002. P. 1308-1310

23552 PATENT TRADEMARK OFFICE	DATE CONSIDERED
	EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.